Despite recent advances in the treatment of autoimmune and inflammatory diseases, unmet
medical needs in some areas still exist. One of the main therapeutic approaches to alleviate …

Drugs targeting the cell cycle–regulatory cyclin-dependent kinase (CDK) 4 and 6 have been
approved for the treatment of hormone receptor–positive breast cancer, and inhibitors …

Over the past two decades there has been a great deal of interest in the development of
inhibitors of the cyclin-dependent kinases (CDKs). This attention initially stemmed from …

Circulating tumor cells (CTC) released into blood from primary cancers and metastases
reflect the current status of tumor genotypes, which are prone to changes. Here, we …

Many solid cancers display cellular hierarchies with self-renewing, tumorigenic stemlike
cells, or cancer-initiating cells (CICs) at the apex. Whereas CICs often exhibit relative …

The Mediator complex is a multi-subunit assembly that appears to be required for regulating
expression of most RNA polymerase II (pol II) transcripts, which include protein-coding and …

We have conducted a detailed transcriptomic, proteomic and phosphoproteomic analysis of
CDK8 and its paralog CDK19, alternative enzymatic components of the kinase module …

The Mediator-associated kinases CDK8 and CDK19 function in the context of three
additional proteins: CCNC and MED12, which activate CDK8/CDK19 kinase function, and …

The nuclear factor-κB (NFκB) family of transcription factors has been implicated in
inflammatory disorders, viral infections, and cancer. Most of the drugs that inhibit NFκB show …

Breast cancers (BrCas) that overexpress oncogenic tyrosine kinase receptor HER2 are
treated with HER2-targeting antibodies (such as trastuzumab) or small-molecule kinase …